At Kura Oncology, our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives, and we recognize the critical role that healthcare providers play in achieving that mission.
We believe that precision medicines represent the future of cancer treatment, offering physicians the potential for smarter, safer and more effective ways to treat cancer.
We are advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our lead candidate is tipifarnib, a farnesyl transferase inhibitor that is currently being studied in multiple Phase 2 clinical studies, including HRAS mutant head and neck squamous cell carcinomas (HNSCC), peripheral T-cell lymphomas (PTCL), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
For questions regarding our ongoing clinical studies or potential investigator-initiated research, please contact firstname.lastname@example.org or (617) 588-3755.
You can also find more information about our programs below.
Kura Oncology, Inc. (Headquarters)
3033 Science Park Road, Suite 220
San Diego, CA 92121
Kura Oncology, Inc. (Clinical Development)
55 Cambridge Parkway, Suite 101
Cambridge, MA 02142
Disclaimer: The information you have requested is not provided by Kura Oncology but by a third party and is not intended to be relied on for investment purposes. Kura Oncology does not guarantee the accuracy or completeness of this information and is not liable for any delays, inaccuracies, errors in, or omissions of any such information, or for any actions taken in reliance on this information, or for any damages arising therefrom